Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Zacks Investment Research Inc.
$12.00
Provider: Reuters Investment Profile
$20.00
Provider: Zacks Investment Research Inc.
$12.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Kamada Ltd Lowers FY 2013 Revenue Guidance


Tuesday, 29 Oct 2013 07:00am EDT 

Kamada Ltd announced that it is revising fiscal 2013 revenue guidance and now expects total revenue for the year to be between $70 million and $72 million, compared with previous guidance for total revenue to be $74 million. This revision is mainly due to a countrywide pricing change enacted by the national drug pricing regulator in India, National Pharmaceutical Pricing Authority, which affects the Company's distributor sales in India. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report revenue of $72 million for fiscal 2013. 

Company Quote

1549.0
-48.0 -3.01%
10:55am EDT